Completed
A Plaque Test Comparing 4 Steroids With Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris
What is being tested
Daivobet® ointment
+ Betnovat® ointment
+ Diprosalic ointment
Drug
Who is being recruted
Over 18 Years
+11 Eligibility Criteria
How is the trial designed
Other Study
Phase 2
Interventional
Study Start: January 2009
Summary
Principal SponsorLEO Pharma
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: January 1, 2009
Actual date on which the first participant was enrolled.The purpose of the study is to compare the anti-psoriatic effect of marketed products with Daivobet® ointment in a plaque test
Official TitleA Plaque Test Comparing 4 Steroids With Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris
Principal SponsorLEO Pharma
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
24 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other Study
Some studies explore topics that don't fall into a specific category. These might include innovative research, new technologies, or emerging healthcare areas.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Criteria
5 inclusion criteria required to participate
Subjects having understood and signed an informed consent form
All skin types
Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk. The lesions must have a total size suitable for application. The subjects should be asked if their lesions have been stable
Subjects willing and able to follow all the study procedures and complete the whole study
Show More Criteria
6 exclusion criteria prevent from participating
Females who are pregnant, of child-bearing potential and who wish to become pregnant during the study, or who are breast feeding
Subjects using biological therapies (marketed or not marketed) with a possible effect on psoriasis (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to study drug administration
Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D-analogues, retinoids, immunosuppressants) within the 4-week period prior to randomisation
Subjects using one of the following topical drugs for the treatment of psoriasis within four (4) weeks prior to study drug administration: - Potent or very potent (WHO group III-IV) corticosteroids - PUVA or Grenz ray therapy
Show More Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Suspended
LEO Pharma Investigational Site
Saint Quentin Yvelines Cedex, FranceOpen LEO Pharma Investigational Site in Google MapsCompletedOne Study Center